| Therapeutic | Erenumab |
| Target | CALCRL |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS |
| Light Chain | QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL |
| 100% seqID Fv Structure | 6umh [Fvs: HL], 6umi [Fvs: HL], 6umj [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6umh [Fvs: HL] |
| 100% seqID Structure | 6umi [Fvs: HL] |
| 100% seqID Structure | 6umj [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | NFD |
| Recorded Developmental Technology | Abgenix XenoMouse |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Amgen, Novartis |
| Conditions Approved | Migraine |
| Conditions Active | na |
| Conditions Discontinued | Hot flashes |
| Notes |
